Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Liver X receptor marks the spot

Multiple companies have shelved liver X receptor agonists for cardiovascular indications because of unfavorable effects on lipid levels. Now, a New York team and Rgenix Inc. have found a different role for the agonists in metastatic melanoma.1

The group, led by The Rockefeller University assistant professor Sohail Tavazoie, came upon the nuclear hormone receptor as a melanoma target while studying the effect of apolipoprotein E (APOE) on cancer metastasis.

APOE is the protein component of cholesterol-carrying lipoprotein particles.

In 2012, Tavazoie's team discovered that Apoe produced by noncancerous tissue combats melanoma vascularization and metastasis.2

"In our previous paper we used an unbiased approach to show

Read the full 1011 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE